NCT02088645View on ClinicalTrials.gov

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Thyroid Cancer, MedullaryNeuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2Neuroendocrine Tumor GEP Grade 1-3
Interventions
DRUG

177Lu-PP-F11N

Trial Locations (1)

4031

University Hospital Basel, Clinic for radiology and nuclear medicine, Basel

All Listed Sponsors
collaborator

Krebsforschung Schweiz, Bern, Switzerland

OTHER

collaborator

Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland

OTHER

collaborator

University Hospital, Zürich

OTHER

collaborator

University Hospital Freiburg

OTHER

lead

University Hospital, Basel, Switzerland

OTHER